Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
By
Rich Duprey
3h agoen
Source
24/7 Wall St.Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity247wallst.comThe pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow process measured in years and billions of dollars, is increasingly becoming a data-driven competition. Companies that combine proprietary medical data with AI tools may gain an advantage similar to what technology companies achieved during the ... Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
You might also wanna read
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Bars·4d ago
AI Drug Discovery Startup Chai Discovery Attracts Pfizer, Eli Lilly; Seeks $400M at $3.4B Valuation
AI drug discovery startup Chai Discovery, founded just 15 months ago, released an antibody-designing AI model that generated intense interes
forbes.com·1mo agoJohnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?
Bars·4d ago
NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Accelerate Drug Discovery
NVIDIA and Eli Lilly have launched an AI co-innovation lab in the San Francisco Bay Area, committing up to $1 billion over five years to acc
briefly.co·1mo agoEli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
Bars·21h ago
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
Bars·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.